Generic Name / Brand Name
Classification
Mode of Action
Measure of Action
Doses
Tobramycin / TOBI
Aminoglycoside
Inhibits protein synthesis by binding to the bacterial ribosomes on the 30s subunit. Without production of new protein, the bacterial cell dies.
Pulmonary Function: Increased FEV1
Laboratory tests: Decreased colonization of
Pseudomonas aeruginosa in the sputum of Cystic Fibrosis patients.
Inhalation (Adults/Children over 6 yrs) :
IM / IV (Adults):
4 – 7 mg/kg once daily
300 mg / 5 ml ampoule, BID for 28 days followed by 28 days off the drug
IM / IV (Children over 5 yrs): up to 13 mg/kg/day divided every 6 – 8 hours
Therapeutic Uses
Contraindications
Tobramycin is given to treat and manage chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Tobramycin is contraindicated in pregnant patients as it can cause fetal harm, and it is not advised for patients with hypersensitivity to aminoglycosides.
Side Effects or Precautions Inhalation:

Voice alteration

Tinnitus


Slight increase in drug resistance
IV / IM:

Ototoxicity (auditory / vestibular / vertigo)

Nephrotoxicity

Neuromuscular blockade

Hypomagnesemia

Cross-allergenicity

Fetal harm resulting in congenital deafness